Hidehito Horinouchi and Martin Reck
May 26, 2025, 09:46
Hidehito Horinouchi Shared ASCO 2025 Abstract on Relatlimab Biology in Metastatic NSCLC
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:
“ASCO 2025 Abstract
Lung Cancer Poster
Unraveling relatlimab-specific biology: Biomarker analyses in pts with metastatic NSCLC treated with 1L nivolumab + RELA high-dose and chemotherapy
Martin Reck, Poster Bd7, Abstr8527″
Abstract Title: Unraveling relatlimab (RELA)-specific biology: Biomarker analyses in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with 1L nivolumab (NIVO) + RELA high-dose (HD) and platinum-doublet chemotherapy (PDCT).
Authors: Martin Reck, Jaclyn Neely, Vamsidhar Velcheti, Sheida Hayati, Annie Yu, Korey Demers, Michael Schenker, Manuel Cobo, Mauricio Burotto, Francisco Orlandi, Priyanka Kasbekar, Anila Qureshi, Charlie Garnett-Benson, Nicolas Girard
Read Full Abstract on ASCO.
More Posts Featuring Hidehito Horinouchi on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 26, 2025, 09:47
May 26, 2025, 09:29
May 26, 2025, 09:13
May 26, 2025, 08:40
May 26, 2025, 08:29